Huge turnout for @thomashopemd "Rethinking FAPI targeted therapy" @EANM_NucMed #EANM26 Best overview talk in the FAPI landscape I have heard. The lowish uptake and low retention compared to PSMA or DOTATATE is a big challenge but one that many groups are trying to address

#ProPSMA celebrates 2500 citations today @declangmurphy @TheLancet thelancet.com/journals/lance…

Check-out the @urotoday coverage of @pros_tic #ProsTIC26 urotoday.com/conference-high… Thanks @zklaassen_md for travelling to Melbourne to cover the meeting live. @PCF_Science Coverage growing by the hour!

A great reminder from @kjaer_andreas @ @SNM_MI : Radioligand therapy is not just “an ADC with radiation.” For ADCs, internalisation is usually essential: the payload must get inside the cancer cell. For RLT, the target mainly acts as a radiation anchor. Internalisation can help, but it is not always required. Radiation can also treat nearby tumour cells through crossfire - an advantage when target expression is heterogeneous. In theranostics, target biology matters - but so does physics, residence time and dosimetry. Great session “Basics of Cancer Biology of Theranostics,” in the session “Identifying and Validating New Molecular Targets and Therapeutic Contexts.” featuring Claudin (@ShadiEsfahani ), GRPR (Vikas Prasad), LRRC15 (David Ulmert) and CAIX (@drmfhoman). With Hossein Jadvar @RadiologyUSC & @PackardAnnie . #SNMMI26

If PROTEUS can randomised >2000 patients, do you think we can do a LuTectomy RCT of similar order of magnitude? @declangmurphy @RenuEapen – at Los Angeles, CA

Excited to share results from the EQUIP study, just presented at @SNM_MI in Los Angeles. #SNMMI26 Last November, we installed the world's first @GEHealthCare Omni Total Body PET/CT - a 128cm long-axis field-of-view system with next-generation digital detectors. These are the first clinical results from anywhere in the world on this device. The short version: better images, in a fraction of the time. We enrolled 25 patients in a direct intra-individual comparison - same patient, same tracer injection, scanned first on a conventional PET/CT and then immediately on the Total Body system. Tracers included F-18 FDG, Ga-PSMA & DOTATATE, F-18 DCFPyL, and I-124. Striking results:: 83% reduction in acquisition time (2.5 min vs 15 min) - with superior image quality, and significantly better sharpness and lesion conspicuity. Remarkably, in 68% of patients, reviewers identified small lesions on Total Body PET that would have been missed on conventional imaging. Congratulations to Dr Alicia Corlett for an awesome oral presentation, Dr Cameron Pain, @pj_physics and all the co-investigators. Thanks to @Cancer_Research , @NIFAus, @unimelb and @PCF_Science for supporting this research. This was an investigator-initiated trial, funded by GE HealthCare. Link to abstract and images in comments..

Lutetium-177 PSMA RLT has shifted the paradigm in mCRPC, but we always need a reality check 🔬 The Good: Unparalleled theranostic precision: tumour shrinkage, major Quality of Life improvements 🛑 The Catch: Disease recurrence remains virtually inevitable. Why? It struggles to suppress micrometastatic or heterogeneous disease. 🔮 The Future: Moving to earlier-line therapy, adaptive dosing, & next-gen alpha or Auger-electron emitters (like Terbium-161 and Lead-212). The goal? Turning favourable initial responses into durable cures. Full insights just published in European Urology Focus 👇 authors.elsevier.com/a/1nBKS…

10 years ago there may have been zero or maybe one ☢️ nuclear medicine abstracts at @ASCO. Theranostics is now🔥. This year, ~90 presentations and a dedicated oral session. For those attending @SNM_MI , we are doing a live cross with @HJacene . Mon June 1, 2026 4:45 PM room 515A

Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. uroweb.org/news/scan-that-ma…

🔥@TheLancetOncol : PSMA-PET risk groups redefine prognosis in prostate cancer: in 11,154 patients; visual and quantitative nomograms predicted 3-, 5-, and 7-year survival. Major step for PET-based trial design, and guideline integration. authors.elsevier.com/sd/arti…